313 related articles for article (PubMed ID: 24668563)
1. Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors.
Rizzardi AE; Vogel RI; Koopmeiners JS; Forster CL; Marston LO; Rosener NK; Akentieva N; Price MA; Metzger GJ; Warlick CA; Henriksen JC; Turley EA; McCarthy JB; Schmechel SC
Cancer; 2014 Jun; 120(12):1800-9. PubMed ID: 24668563
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronan (HA) interacting proteins RHAMM and hyaluronidase impact prostate cancer cell behavior and invadopodia formation in 3D HA-based hydrogels.
Gurski LA; Xu X; Labrada LN; Nguyen NT; Xiao L; van Golen KL; Jia X; Farach-Carson MC
PLoS One; 2012; 7(11):e50075. PubMed ID: 23166824
[TBL] [Abstract][Full Text] [Related]
3. Identification, design and synthesis of tubulin-derived peptides as novel hyaluronan mimetic ligands for the receptor for hyaluronan-mediated motility (RHAMM/HMMR).
Esguerra KV; Tolg C; Akentieva N; Price M; Cho CF; Lewis JD; McCarthy JB; Turley EA; Luyt LG
Integr Biol (Camb); 2015 Dec; 7(12):1547-60. PubMed ID: 26456171
[TBL] [Abstract][Full Text] [Related]
4. Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice.
Simpson MA
Am J Pathol; 2006 Jul; 169(1):247-57. PubMed ID: 16816377
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing.
Bharadwaj AG; Kovar JL; Loughman E; Elowsky C; Oakley GG; Simpson MA
Am J Pathol; 2009 Mar; 174(3):1027-36. PubMed ID: 19218337
[TBL] [Abstract][Full Text] [Related]
6. The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder.
Niedworok C; Kretschmer I; Röck K; Vom Dorp F; Szarvas T; Heß J; Freudenberger T; Melchior-Becker A; Rübben H; Fischer JW
PLoS One; 2013; 8(9):e75681. PubMed ID: 24069434
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.
Ekici S; Cerwinka WH; Duncan R; Gomez P; Civantos F; Soloway MS; Lokeshwar VB
Int J Cancer; 2004 Oct; 112(1):121-9. PubMed ID: 15305383
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of protein biomarkers of prostate cancer aggressiveness.
Rizzardi AE; Rosener NK; Koopmeiners JS; Isaksson Vogel R; Metzger GJ; Forster CL; Marston LO; Tiffany JR; McCarthy JB; Turley EA; Warlick CA; Henriksen JC; Schmechel SC
BMC Cancer; 2014 Apr; 14():244. PubMed ID: 24708576
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells.
Song JM; Im J; Nho RS; Han YH; Upadhyaya P; Kassie F
Mol Carcinog; 2019 Mar; 58(3):321-333. PubMed ID: 30365189
[TBL] [Abstract][Full Text] [Related]
10. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor.
Ghatak S; Hascall VC; Markwald RR; Misra S
J Biol Chem; 2010 Jun; 285(26):19821-32. PubMed ID: 20200161
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells.
Twarock S; Tammi MI; Savani RC; Fischer JW
J Biol Chem; 2010 Jul; 285(30):23276-84. PubMed ID: 20463012
[TBL] [Abstract][Full Text] [Related]
12. Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis.
Bharadwaj AG; Rector K; Simpson MA
J Biol Chem; 2007 Jul; 282(28):20561-72. PubMed ID: 17502371
[TBL] [Abstract][Full Text] [Related]
13. Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.
Song JM; Molla K; Anandharaj A; Cornax I; O Sullivan MG; Kirtane AR; Panyam J; Kassie F
Oncotarget; 2017 Apr; 8(16):26927-26940. PubMed ID: 28460475
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of hyaluronan, HAS1-2, and HYAL1-2 in oral lichen planus.
Siponen M; Kullaa A; Nieminen P; Salo T; Pasonen-Seppänen S
J Oral Pathol Med; 2015 Jul; 44(6):401-9. PubMed ID: 25421996
[TBL] [Abstract][Full Text] [Related]
15. Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content.
Nykopp TK; Rilla K; Sironen R; Tammi MI; Tammi RH; Hämäläinen K; Heikkinen AM; Komulainen M; Kosma VM; Anttila M
BMC Cancer; 2009 May; 9():143. PubMed ID: 19435493
[TBL] [Abstract][Full Text] [Related]
16. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer.
Lipponen P; Aaltomaa S; Tammi R; Tammi M; Agren U; Kosma VM
Eur J Cancer; 2001 May; 37(7):849-56. PubMed ID: 11313172
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome.
Josefsson A; Adamo H; Hammarsten P; Granfors T; Stattin P; Egevad L; Laurent AE; Wikström P; Bergh A
Am J Pathol; 2011 Oct; 179(4):1961-8. PubMed ID: 21854754
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronan Mediated Motility Receptor (HMMR) Encodes an Evolutionarily Conserved Homeostasis, Mitosis, and Meiosis Regulator Rather than a Hyaluronan Receptor.
He Z; Mei L; Connell M; Maxwell CA
Cells; 2020 Mar; 9(4):. PubMed ID: 32231069
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer.
Posey JT; Soloway MS; Ekici S; Sofer M; Civantos F; Duncan RC; Lokeshwar VB
Cancer Res; 2003 May; 63(10):2638-44. PubMed ID: 12750291
[TBL] [Abstract][Full Text] [Related]
20. TGFβ and Hippo Pathways Cooperate to Enhance Sarcomagenesis and Metastasis through the Hyaluronan-Mediated Motility Receptor (HMMR).
Ye S; Liu Y; Fuller AM; Katti R; Ciotti GE; Chor S; Alam MZ; Devalaraja S; Lorent K; Weber K; Haldar M; Pack MA; Eisinger-Mathason TSK
Mol Cancer Res; 2020 Apr; 18(4):560-573. PubMed ID: 31988250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
